Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
There have been no clinical trials for approval of medications for treating multiple sclerosis in patients under the age of 18 years. All treatments are based on personal experience and data from open observational studies. Fingolimod is an oral drug for treating multiple sclerosis that has proven to be efficient and safe in adults. Fingolimod showed a good safety and efficacy profile in these patients, all of whom had very active multiple sclerosis.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi